Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/<i>neu</i>Peptide (AE37) Vaccine

Abstract

The hybrid AE37 vaccine seems safe and well tolerated with minimal toxicity if properly dosed. AE37 is capable of eliciting HER-2/neu-specific immune responses, even without the use of an adjuvant. This trial represents the first human experience with the Ii-Key modification, and to our knowledge, AE37 is the first peptide vaccine to show potency in the absence of an immunoadjuvant.